Fusion protein will be produced, and clinical studies will begin in the summer of 2008.

Laureate Pharma entered into a cGMP contract manufacturing agreement with Enobia Pharma, which is engaged in the development of enzyme replacement therapy for the treatment of hypophosphatasia.

Laureate will produce Enobia Pharma’s fusion protein for this rare and sometimes fatal metabolic bone disease characterized by skeletal hypomineralization. Enobia anticipates initiating clinical studies in this lead program  in the summer of 2008.

Previous articleNew Genes Implicated in MS
Next articleSilence Therapeutics and Quark Pharmaceuticals Amend AtuRNAi Agreement